Understand the source comparison
Efficacy Comparison: What Research Shows
Muscle growth magnitude: ACE-031: 50-100% improvements in muscle mass and strength in animal models Follistatin: Similar or slightly greater improvements (broader TGF-β inhibition) Difference: Modest; both are effective Disease model efficacy: DMD (mdx mice):
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Muscle growth magnitude:
- ACE-031: 50-100% improvements in muscle mass and strength in animal models
- Follistatin: Similar or slightly greater improvements (broader TGF-β inhibition)
- Difference: Modest; both are effective
- Disease model efficacy:
- DMD (mdx mice): Both reduce inflammation and improve muscle phenotype
- SMA: Limited Follistatin data; ACE-031 more extensively studied
- Ageing: Both show promise; ACE-031 more studied in senescent models
- Clinical efficacy (limited data):
- ACE-031: DMD trials showed modest but significant strength improvements
- Follistatin: Limited human data; mostly preclinical or early-phase studies
- Efficacy appears comparable; ACE-031 has more robust clinical evidence.